Literature DB >> 10672289

The effect of aminophylline infusion on the exercise capacity in patients with syndrome X.

O Yeşildağ1, M Yazici, O Yilmaz, R Uçar, O Sağkan.   

Abstract

Aminophylline was known to decrease effort angina and ischaemia in patients with coronary artery disease and stable angina. This effect has been explained by the antagonization of the vasodilatation caused by adenosine and the prevention of the transmural myocardial maldistribution (steal phenomenon). In this study, treadmill exercise tests (with Bruce protocol) were performed in 14 patients (11 women, 3 men, mean age 51 +/- 9.9 years) diagnosed with syndrome X (typical anginal chest pain, abnormal stress test, normal coronary angiography) before (basal condition) and after the acute i.v. aminophylline infusion (total dosage 6 mg/kg within 15 minutes). It was shown that aminophylline lengthened the time before the occurrence of ischaemia in patients with syndrome X by increasing the ischaemia threshold in spite of the occurrence of tachycardia but it had no effect on the total exercise duration. Aminophylline infusion also exerted a beneficial effect on exercise-induced chest pain. It has been suggested that the role of the adenosine receptor could be important in the pathogenesis of syndrome X.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672289

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  8 in total

Review 1.  Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

Authors:  C Noel Bairey Merz; Carl J Pepine; Mary Norine Walsh; Jerome L Fleg
Journal:  Circulation       Date:  2017-03-14       Impact factor: 29.690

Review 2.  Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease).

Authors:  Christine Pacheco Claudio; Odayme Quesada; Carl J Pepine; C Noel Bairey Merz
Journal:  Clin Cardiol       Date:  2018-03-02       Impact factor: 2.882

Review 3.  Contemporary treatment of Western and Chinese medicine for cardiac syndrome X.

Authors:  Ying-Fei Bi; Jing-Yuan Mao; Xian-Liang Wang; Heng-He Wang; Yong-Bin Ge; Zhen-Peng Zhang
Journal:  Chin J Integr Med       Date:  2011-04-21       Impact factor: 1.978

Review 4.  Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review.

Authors:  Federico Marchini; Graziella Pompei; Emanuele D'Aniello; Andrea Marrone; Serena Caglioni; Simone Biscaglia; Gianluca Campo; Matteo Tebaldi
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-09       Impact factor: 3.727

5.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 6.  Vasomotor Dysfunction in Patients with Ischemia and Non-Obstructive Coronary Artery Disease: Current Diagnostic and Therapeutic Strategies.

Authors:  Amr Abouelnour; Tommaso Gori
Journal:  Biomedicines       Date:  2021-11-26

Review 7.  Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.

Authors:  Balaj Rai; Janki Shukla; Timothy D Henry; Odayme Quesada
Journal:  Cells       Date:  2021-05-08       Impact factor: 7.666

Review 8.  Treatment of coronary microvascular dysfunction.

Authors:  C Noel Bairey Merz; Carl J Pepine; Hiroki Shimokawa; Colin Berry
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 13.081

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.